GHK-Cu for Injury Recovery: Protocol, Dosing, and What to Expect
Evidence strength: moderate
What this protocol is for
GHK-Cu in injury recovery is a moderate use case anchored on the tripeptide's original characterised role: tissue regeneration and wound healing. The molecule supports collagen synthesis, angiogenesis, fibroblast activity, and the matrix-organisation signaling that injured tissue depends on for proper remodeling. Mechanism overlap with BPC-157 and TB-500 is substantial; the differentiation is that GHK-Cu contributes most to the collagen and matrix-protein layer of recovery rather than the local soft-tissue and systemic cell-migration layers those compounds handle.
The clinical pattern in user reports is consistent. GHK-Cu fits as the connective-tissue and skin-component layer in stacked recovery protocols. Tendon insertions with significant scar-tissue history. Skin and wound healing post-surgery. Chronic joint pain where matrix integrity is part of the picture. Anecdotally, users running GHK-Cu alongside BPC-157 and TB-500 report better scar quality (less raised, more flexible), faster surface-tissue healing, and improved skin appearance around injection sites.
Used by many in the recovery / biohacking space as a tertiary layer in serious recovery stacks rather than a primary protocol. For straightforward soft-tissue injuries that respond to BPC-157 and TB-500 alone, adding GHK-Cu does not deliver enough additional value to justify the extra dosing complexity. For chronic cases with significant matrix or scar tissue issues, the layer earns its place. Run this as a tactical, legal performance layer at the connective-tissue level.
Dose for injury recovery
1 to 2 mg subcutaneous daily during the recovery window. Some protocols use intramuscular near the injury site for deeper-tissue cases, though subcutaneous abdomen is the safer default. Topical can be added for surface wound or scar areas alongside the systemic dose.
Cycle length
4 to 8 weeks aligned with the local peptide protocol (BPC-157, TB-500) and the physio timeline. Start at the same window as the local peptides (typically 1 to 2 weeks post-injury or post-op after clearance). Cycle off when the local protocol completes.
Stack pairings
Commonly stacked with BPC-157 and TB-500.
Expected timeline
Week 1–2: surface healing accelerates if there is a skin or wound component. Week 2–4: deeper matrix and collagen effects begin to layer onto the work BPC-157 and TB-500 are doing. Week 4–8: cumulative tissue quality effects (scar appearance, connective-tissue flexibility) become visible. Most users notice scar quality differences post-cycle rather than during.
Common mistakes
- Running GHK-Cu alone for injury recovery. The peptide supports matrix and collagen work; without BPC-157 or TB-500 covering the local soft tissue and systemic cell-migration layers, the recovery is missing the primary biology.
- Adding GHK-Cu for trivial soft-tissue injuries that BPC-157 alone handles. The added dosing complexity does not pay back for minor cases.
- Topical-only use for deep-tissue injuries. Topical addresses surface skin and scalp; for deeper tissue work, subcutaneous is required.
- Expecting GHK-Cu to deliver dramatic single-cycle effects. The contribution is matrix-quality and connective-tissue support, which is back-loaded and cumulative; the visible effects are post-cycle scar and tissue-quality differences rather than in-cycle dramatic change.